Abstract 414P
Background
Brain metastases (BMs) affect approximately half of the patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and holds a poor prognosis. Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, has shown promising results in patients with breast cancer brain metastases (BCBMs). Thus, we conducted a systematic review and meta-analysis to evaluate the effectiveness and safety of T-DXd in the HER2-positive BCBM population.
Methods
We searched PubMed, Embase, and Cochrane Library databases, as well as ASCO, ESMO, and SABCS websites for clinical trials (CTs) and observational studies evaluating T-DXd in the HER2-positive BCBM patients. Heterogeneity was assessed with the Cochran Q test and I2 statistics. Random effects models were used for all statistical analyses, which were performed using R software (v.4.2.2).
Results
Ten studies were included, six clinical trials (N=189) and four observational studies (N=147), with a total of 336 patients. The mean progression-free survival was 15 months (95% CI 13.9 to 16.1 months). The objective response rate (ORR) was 61% (95% CI 53-68%), and the intracranial (IC)-ORR was 62% (95% CI 55-70%). No significant differences in ORR and IC-ORR were observed between CTs and observational studies (p=0.56, and p=0.46, respectively). The clinical benefit rate (CBR) was 86% (95% CI 72-94%), and the IC-CBR was 69% (95% CI 59-79%). The ORR was 64% (95% CI 53-73%) in the subgroup of patients with stable BMs and 61% (95% CI 49-73%) in patients with active BMs, with no significant difference between groups (p=0.78). Adverse events (AE) of any grade were reported in 98% of cases (95% CI 90-100%). Dose reduction and drug interruption due to AE were reported in 29% (95% CI 10-60%) and 31% (95% CI 19-42%) of cases, respectively.
Conclusions
Our systematic review and meta-analysis supports the intracranial activity of T-DXd in both patients with stable BM and active BM. HER2-positive BCBM patients treated with T-DXd achieved ORR and IC-ORR higher than 50% in the clinical trials setting and in real-world data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
424P - Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer: Updated survival results from the phase II PICTURE trial
Presenter: Xichun Hu
Session: Poster session 03
425P - Real world quality of life (QoL) in breast cancer (BC) patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i)
Presenter: Blanca Tavara
Session: Poster session 03
427P - Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
Presenter: biyun Wang
Session: Poster session 03
428P - Palbociclib dose patterns in Swedish patients with metastatic breast cancer: 5-year update from the SIRI study
Presenter: Antonis Valachis
Session: Poster session 03
429P - The impact of HER2 status on the efficacy of CDK 4/6 inhibitors: A multicenter study
Presenter: Hasan Yildirim
Session: Poster session 03
430P - Real-world patient characteristics and treatment patterns in HR+/HER2+ metastatic breast cancer patients in 5 European countries
Presenter: Carmen Criscitiello
Session: Poster session 03
431P - Distribution and prognostic role of HER2 status of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) in HER2- metastatic breast cancer (MBC) patients (pts)
Presenter: Eleonora Nicolo
Session: Poster session 03
432P - Ki67 and progesterone receptor status could be predict sensitivity to cyclin-dependent kinase inhibitor
Presenter: Lucia Navarro Berlanga
Session: Poster session 03
433P - Effectiveness and safety of vinorelbine + inetetamab + pyrotinib in ≥second-line treatment of HER2-positive metastatic breast cancer
Presenter: Wu Fan
Session: Poster session 03